Evidence-based sizing of non-inferiority trials using decision models

[1]  S. Dewilde,et al.  Health state utilities in non–small cell lung cancer: An international study , 2017, Asia-Pacific journal of clinical oncology.

[2]  R. Jagsi.  Early-stage breast cancer: falling risks and emerging options , 2017, The Lancet.

[3]  Curtis R. Heberle,et al.  Radiofrequency Ablation of Barrett's Esophagus Reduces Esophageal Adenocarcinoma Incidence and Mortality in a Comparative Modeling Analysis , 2017, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[4]  P. Gibbs,et al.  Mapping EORTC-QLQ-C30 to EQ-5D-3L in patients with colorectal cancer , 2017, Journal of medical economics.

[5]  Bingshu E. Chen,et al.  Effect of Standard Radiotherapy With Cisplatin vs Accelerated Radiotherapy With Panitumumab in Locoregionally Advanced Squamous Cell Head and Neck Carcinoma: A Randomized Clinical Trial , 2017, JAMA oncology.

[6]  C. May,et al.  Development and validation of the Patient Experience with Treatment and Self-management (PETS): a patient-reported measure of treatment burden , 2017, Quality of Life Research.

[7]  P. Clarke,et al.  Using Patient-Reported Outcomes for Economic Evaluation: Getting the Timing Right. , 2016, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[8]  T. D’amico,et al.  Patient Preferences in Treatment Choices for Early-Stage Lung Cancer. , 2016, The Annals of thoracic surgery.

[9]  M. Ratain,et al.  Measuring financial toxicity as a clinically relevant patient‐reported outcome: The validation of the COmprehensive Score for financial Toxicity (COST) , 2016, Cancer.

[10]  James R Carpenter,et al.  Non-inferiority trials: are they inferior? A systematic review of reporting in major medical journals , 2016, BMJ Open.

[11]  T. Delea,et al.  Cost-effectiveness of pazopanib compared with sunitinib in metastatic renal cell carcinoma in Canada. , 2016, Current oncology.

[12]  Y. Hao,et al.  A structured review of health utility measures and elicitation in advanced/metastatic breast cancer , 2016, ClinicoEconomics and outcomes research : CEOR.

[13]  Karen M Kuntz,et al.  Estimation of Benefits, Burden, and Harms of Colorectal Cancer Screening Strategies: Modeling Study for the US Preventive Services Task Force. , 2016, JAMA.

[14]  P. Fayers,et al.  Using Linear Equating to Map PROMIS® Global Health Items and the PROMIS-29 V2.0 Profile Measure to the Health Utilities Index Mark 3 , 2016, PharmacoEconomics.

[15]  M. Hernán,et al.  Rationale and design of the European Polyp Surveillance (EPoS) trials , 2016, Endoscopy.

[16]  S. Mitchell,et al.  Examining the Value of Menopausal Symptom Relief Among US Women. , 2016, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[17]  J. Marshall,et al.  Patient preference and decision-making for initiating metastatic colorectal cancer medical treatment , 2016, Journal of Cancer Research and Clinical Oncology.

[18]  Tracey L Marsh,et al.  Validation of Models Used to Inform Colorectal Cancer Screening Guidelines , 2016, Medical decision making : an international journal of the Society for Medical Decision Making.

[19]  C. Kerr,et al.  Health-Related Quality of Life and Health Utilities in Metastatic Castrate-Resistant Prostate Cancer: A Survey Capturing Experiences from a Diverse Sample of UK Patients. , 2015, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[20]  Jipan Xie,et al.  Economic Evaluations of Everolimus Versus Other Hormonal Therapies in the Treatment of HR+/HER2- Advanced Breast Cancer From a US Payer Perspective. , 2015, Clinical breast cancer.

[21]  Wei Shi,et al.  Identification of a Low-Risk Luminal A Breast Cancer Cohort That May Not Benefit From Breast Radiotherapy. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  Christopher D. Jensen,et al.  Variation in Adenoma Detection Rate and the Lifetime Benefits and Cost of Colorectal Cancer Screening: A Microsimulation Model. , 2015, JAMA.

[23]  H. D. de Koning,et al.  The value of models in informing resource allocation in colorectal cancer screening: the case of the Netherlands , 2015, Gut.

[24]  M. Parmar,et al.  Whole brain radiotherapy for brain metastases from non-small lung cancer: Quality of life (QoL) and overall survival (OS) results from the UK Medical Research Council QUARTZ randomised clinical trial (ISRCTN 3826061). , 2015 .

[25]  Ruth Etzioni,et al.  Personalizing age of cancer screening cessation based on comorbid conditions: model estimates of harms and benefits. , 2014, Annals of internal medicine.

[26]  R. Knecht,et al.  New treatment strategies for HPV-positive head and neck cancer , 2014, European Archives of Oto-Rhino-Laryngology.

[27]  J. Habbema,et al.  Should colorectal cancer screening be considered in elderly persons without previous screening? A cost-effectiveness analysis. , 2014, Annals of internal medicine.

[28]  R. Hays,et al.  Demographic Differences in Health Preferences in the United States , 2014, Medical care.

[29]  William Hazelton,et al.  Benefits and Harms of Computed Tomography Lung Cancer Screening Strategies: A Comparative Modeling Study for the U.S. Preventive Services Task Force , 2014, Annals of Internal Medicine.

[30]  J. Bijlsma,et al.  Dose REduction strategy of subcutaneous TNF inhibitors in rheumatoid arthritis: design of a pragmatic randomised non inferiority trial, the DRESS study , 2013, BMC Musculoskeletal Disorders.

[31]  Stephen T. Sonis,et al.  The Economic Burden of Toxicities Associated with Cancer Treatment: Review of the Literature and Analysis of Nausea and Vomiting, Diarrhoea, Oral Mucositis and Fatigue , 2013, PharmacoEconomics.

[32]  M. Parmar,et al.  Interim data from the Medical Research Council QUARTZ Trial: does whole brain radiotherapy affect the survival and quality of life of patients with brain metastases from non-small cell lung cancer? , 2013, Clinical oncology (Royal College of Radiologists (Great Britain)).

[33]  D. Rennie,et al.  SPIRIT 2013 statement: defining standard protocol items for clinical trials. , 2013, Annals of internal medicine.

[34]  David Moher,et al.  SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials , 2013, BMJ.

[35]  Jenny Hewison,et al.  The STAR trial protocol: a randomised multi-stage phase II/III study of Sunitinib comparing temporary cessation with allowing continuation, at the time of maximal radiological response, in the first-line treatment of locally advanced/metastatic Renal Cancer , 2012, BMC Cancer.

[36]  E. Scarpi,et al.  Noninferiority Trials in Second-Line Treatments of Nonsmall Cell Lung Cancer: A Systematic Review of Literature With Meta-analysis of Phase III Randomized Clinical Trials , 2012, American journal of clinical oncology.

[37]  J. Berkhof,et al.  Modeling preventative strategies against human papillomavirus-related disease in developed countries. , 2012, Vaccine.

[38]  S. Bowman,et al.  A randomised efficacy and discontinuation study of etanercept versus adalimumab (RED SEA) for rheumatoid arthritis: a pragmatic, unblinded, non-inferiority study of first TNF inhibitor use: outcomes over 2 years , 2012, BMJ Open.

[39]  A. Briggs,et al.  Power and sample size for cost-effectiveness analysis: fFN neonatal screening. , 2011, Contemporary clinical trials.

[40]  J. Habbema,et al.  Cost-effectiveness analysis of a quantitative immunochemical test for colorectal cancer screening. , 2011, Gastroenterology.

[41]  J. Schumi,et al.  TRIALS REVIEW Open Access , 2022 .

[42]  A. Nowacki,et al.  Understanding Equivalence and Noninferiority Testing , 2011, Journal of General Internal Medicine.

[43]  K. Beusterien,et al.  Population preference values for treatment outcomes in chronic lymphocytic leukaemia: a cross-sectional utility study , 2010, Health and quality of life outcomes.

[44]  Hiroshi Nishiyama,et al.  Points to consider on switching between superiority and non-inferiority. , 2006, British journal of clinical pharmacology.

[45]  S. Pocock,et al.  Reporting of noninferiority and equivalence randomized trials: extension of the CONSORT 2010 statement. , 2006, JAMA.

[46]  J. Dowie.  Why cost-effectiveness should trump (clinical) effectiveness: the ethical economics of the South West quadrant. , 2004, Health economics.

[47]  Murray Krahn,et al.  Patient and Community Preferences for Outcomes in Prostate Cancer: Implications for Clinical Policy , 2003, Medical care.

[48]  Andrew R Willan,et al.  Is there a kink in consumers' threshold value for cost-effectiveness in health care? , 2002, Health economics.

[49]  R. Dittus,et al.  Utility valuations for outcome states of colorectal cancer , 1999, American Journal of Gastroenterology.

[50]  Rob Boer,et al.  The MISCAN-COLON Simulation Model for the Evaluation of Colorectal Cancer Screening , 1999, Comput. Biomed. Res..

[51]  H. Akaza,et al.  Randomized Controlled Study of the Efficacy, Safety and Quality of Life with Low Dose bacillus Calmette-Guérin Instillation Therapy for Nonmuscle Invasive Bladder Cancer. , 2016, The Journal of urology.

[52]  Ich Harmonised,et al.  INTERNATIONAL COUNCIL FOR HARMONISATION OF TECHNICAL REQUIREMENTS FOR PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED GUIDELINE GENERAL CONSIDERATIONS FOR CLINICAL STUDIES E8(R1) , 2019 .

[53]  David Moher,et al.  SPIRIT 2013 Statement: defining standard protocol items for clinical trials. , 2015, Revista panamericana de salud publica = Pan American journal of public health.

[54]  V. Retèl,et al.  A Systematic and Critical Review of the Evolving Methods and Applications of Value of Information in Academia and Practice , 2012, PharmacoEconomics.

[55]  G W Torrance,et al.  Toward a utility theory foundation for health status index models. , 1976, Health services research.

[56]  Torrance Gw,et al.  Toward a utility theory foundation for health status index models. , 1976 .